Arrowhead Pharmaceuticals develops and commercializes RNA interference medicines that silence genes associated with intractable diseases. The company’s TRiM™ platform is used to design targeted RNAi therapeutics for tissues including liver, lung, muscle, adipose and central nervous system tissue.
Recurring ARWR news covers REDEMPLO® (plozasiran), an siRNA medicine approved in the United States and Australia as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. Company updates also address plozasiran data across hypertriglyceridemia, regulatory actions in additional geographies, pricing and market-access strategy, fiscal results, investor events, and clinical or partnering developments involving programs such as ARO-PNPLA3, ARO-INHBE and ARO-ALK7.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced proposed public offerings of $500 million aggregate principal amount of convertible senior notes due January 15, 2032 and $200 million of common stock, each with 30-day underwriter overallotment options of $75 million and $30 million, respectively.
Notes will be senior unsecured, accrue interest semi‑annually, be convertible in specified circumstances, and may be redeemable for cash on or after January 16, 2029. Arrowhead intends to use proceeds for capped call hedges, general corporate purposes, R&D, clinical trials, commercialization preparation and possible prepayment of credit facility loans.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced interim Phase 1/2a data for RNAi obesity candidates ARO-INHBE and ARO-ALK7 on January 6, 2026.
Key results: ARO-INHBE plus tirzepatide produced mean weight loss of -9.4% at week 16 versus -4.8% with tirzepatide alone; combination showed -23.2% visceral fat, -15.4% total fat and -76.7% liver fat reductions (week 12 MRI). ARO-INHBE monotherapy reduced visceral fat -9.9% (single dose, week 16) and -15.6% (two doses, week 24). ARO-ALK7 achieved mean adipose ALK7 mRNA knockdown of -88% (200 mg, week 8) and placebo-adjusted visceral fat -14.1% at week 8.
Both agents were generally well tolerated; one SAE (limb abscess) was reported and assessed unrelated to treatment.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that Health Canada issued a Notice of Compliance authorizing REDEMPLO (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) for whom standard therapies are inadequate.
The approval is based on Phase 3 PALISADE data showing a median triglyceride change of -80% on 25 mg REDEMPLO versus -17% for pooled placebo over 12 months, and a lower numerical incidence of acute pancreatitis; common adverse reactions (≥15%) included hyperglycemia, headache, nausea, and injection site reaction. REDEMPLO is the first Health Canada–approved siRNA for FCS and is dosed by subcutaneous self-injection once every three months.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced participation in two January 2026 events: an Obesity KOL Webinar presenting interim clinical data for ARO-INHBE and ARO-ALK7 on January 6, 2026 at 11:30 a.m. ET, and a corporate presentation at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 at 10:30 a.m. ET.
Presentation materials and webcast links, if available, will be posted on the company’s Events and Presentations page under Investors.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that on December 12, 2025 its board approved inducement equity grants for 78 new employees under NASDAQ Rule 5635(c)(4).
The grants entitle those employees, in aggregate, to receive up to 141,310 restricted stock units. The awards are outside the company’s stockholder-approved equity plans and vest annually over four years.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has dosed the first subjects in a Phase 1/2a study of ARO-MAPT, an RNA interference therapeutic targeting the MAPT gene for Alzheimer’s disease and other tauopathies.
ARO-MAPT uses Arrowhead’s TRiM™ delivery platform; preclinical non-human primate data showed blood-brain-barrier penetration and broad CNS knockdown after subcutaneous dosing. The study will test single and multiple doses in healthy volunteers and multiple doses in early Alzheimer’s patients, with initial data expected in second half of 2026. Presentation slides from RNA Leaders USA Congress 2025 are available on Arrowhead’s investor website.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the FDA granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglycerides in adults with severe hypertriglyceridemia (SHTG) (TG ≥ 500 mg/dL).
The company said there are limited treatment options for millions with SHTG. Arrowhead plans to complete the SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 studies in mid-2026 and intends to file a supplemental New Drug Application (sNDA) with the FDA by year-end 2026, then pursue additional global regulatory submissions.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in multiple December 2025 conferences with investor and scientific presentations. Key events include Piper Sandler 37th Annual Healthcare Conference (Dec 2-4; fireside chat Dec 3, 10:30 a.m. ET), Evercore 8th Annual Healthcare Conference (Dec 2-4; fireside chat Dec 4, 10:00 a.m. ET), WCIRDC (Dec 4-6) with multiple presentations on plozasiran and FCS/acute pancreatitis topics, and the 7th Annual CNS Delivery Summit (Dec 9-11; TRiM platform talk Dec 10, 9:30 a.m. ET). Presenters include Norman Lepore, Rohit Loomba, Nihar Desai and Agnieszka Glebocka. Presentation materials and webcast links will be available on the company Events and Presentations page under Investors.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported fiscal year 2025 results for the year ended September 30, 2025 and announced multiple commercial and partnership milestones.
Key facts: FDA approved REDEMPLO (plozasiran) for familial chylomicronemia syndrome (FCS) after Phase 3 PALISADE showed -80% triglycerides; REDEMPLO is self-administered once every three months. Fiscal highlights: Revenue $829,448, operating income $98,346, net loss attributable to Arrowhead $(1,631), and total cash resources $781,524. Major deals: $200M upfront from Novartis, $300M milestones from Sarepta, and $130M upfront from Sanofi (Visirna sale).
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced it earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT) after reaching the second development milestone in the Phase 1/2 study of ARO-DM1 (SRP-1003) for type 1 myotonic dystrophy.
The milestone followed a drug safety committee review, authorization to dose escalate, and attainment of a pre-specified patient enrollment target. Arrowhead said it expects to receive the payment within 60 days. The company reported cohort 4 (6 mg/kg) accrual is nearly complete and plans to begin enrollment in cohort 5 (12 mg/kg) in Q1 2026.